News
NVCR
13.15
+0.31%
0.04
NovoCure (NVCR) Q3 Results Sharpen The Profitability Debate
Simply Wall St · 19h ago
Novocure Price Target Cut to $15.00/Share From $20.00 by Wells Fargo
Dow Jones · 1d ago
Novocure Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 1d ago
Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15
Benzinga · 1d ago
Novocure Price Target Cut to $20.00/Share From $23.00 by Evercore ISI Group
Dow Jones · 1d ago
Novocure Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 1d ago
Novocure price target lowered to $20 from $23 at Evercore ISI
TipRanks · 1d ago
Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20
Benzinga · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NovoCure (NVCR), PTC Therapeutics (PTCT) and Encompass Health (EHC)
TipRanks · 1d ago
Raised Guidance Could Change The Case For NovoCure Stock (NVCR)
Simply Wall St · 1d ago
NovoCure Q3 Earnings Call Highlights
NASDAQ · 1d ago
NovoCure slips despite quarterly beats, updated guidance
Seeking Alpha · 1d ago
Novocure’s Pax disrupted by Revolution rollout, says Wedbush
TipRanks · 2d ago
NovoCure Limited Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
NASDAQ · 2d ago
NovoCure Q3 2026 Earnings Call Transcript
Benzinga · 2d ago
NovoCure Q3 Loss Decreases
NASDAQ · 2d ago
Novocure reports Q3 EPS (9c), consensus (23c)
TipRanks · 2d ago
Novocure raises FY26 revenue view $736M-$743M from $710M-$725M
TipRanks · 2d ago
NovoCure Q3 EPS $(0.09) Beats $(0.24) Estimate, Sales $193.399M Beat $182.233M Estimate
Benzinga · 2d ago
NovoCure Raises FY2026 Sales Guidance from $710.000M-$725.000M to $736.000M-$743.000M vs $725.814M Est
Benzinga · 2d ago
More
Webull provides a variety of real-time NVCR stock news. You can receive the latest news about Novocure through multiple platforms. This information may help you make smarter investment decisions.
About NVCR
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.